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Abstract
A better understanding of dendritic cell (DC) involvement in responses to haptenic drugs is needed, because it represents a 
possible approach to the development of an in vitro test, which could identify patients prone to drug allergies. There are two 
main DC subsets: plasmacytoid DC (pDC) and myeloid DC (mDC). β-lactams form hapten-carrier conjugates and may provide 
a suitable model to study DC behavior in drug allergy reactions. It has been demonstrated that drugs interact differently with 
DC in drug allergic and non-allergic patients, but there are no studies regarding these subsets. Our aim was to assess the 
functional changes of mDC and pDC harvested from an amoxicillin-hypersensitive 32-year-old woman who experienced a se-
vere maculopapular exanthema as reflected in interleukin-6 (IL-6) production after stimulation with this drug and penicillin. We 
also aim to demonstrate, for the first time, the feasibility of this method for dendritic cell isolation followed by in vitro stimulation 
for studies of drug allergy physiopathology. DC were harvested using a double Percoll density gradient, which generates a 
basophil-depleted cell (BDC) suspension. Further, pDC were isolated by blood DC antigen 4-positive magnetic selection and 
gravity filtration through magnetized columns. After stimulation with amoxicillin, penicillin and positive and negative controls, 
IL-6 production was measured by ELISA. A positive dose-response curve for IL-6 after stimulation with amoxicillin and penicil-
lin was observed for pDC, but not for mDC or BDC suspension. These preliminary results demonstrate the feasibility of this 
methodology to expand the knowledge of the effect of dendritic cell activation by drug allergens.
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Adverse reactions to drugs are among the leading 
causes of iatrogenic morbidity and mortality. Severe T 
cell-mediated drug hypersensitivity reactions are a major 
problem both in drug development and in clinical practice. 
The current in vitro methods to confirm diagnosis and to 
indentify the culprit drug are still unreliable and have not 
been standardized. β-lactam antibiotics, the most common 
agents involved in allergic reactions to drugs, form hapten-
carrier conjugates with proteins that can be processed and 
presented by antigen-presenting cells (APC) to naive T 
lymphocytes (1). In hypersensitive subjects, the immune 
system develops either Th2-type responses or delayed 
Th1-type responses and β-lactams provide the best model 
to analyze both types of reactions (2).
The involvement of T cells in these reactions has been 
studied (3) but little is known about the initial steps in the 
hypersensitivity response, consisting of drug allergen 
presentation to the lymphocytes, which is mediated by the 
innate immune response and served mainly by dendritic 
cells (DC). DC are professional APC, essential for initiating 
T-cell responses (4).
There are two main pathways of DC ontogeny from 
hematopoietic progenitor cells. One pathway generates 
plasmacytoid DC (pDC) while the other generates myeloid 
DC (mDC) (5). In human blood, there are two major groups 
based on surface antigens of immature DC (imDC), namely 
CD123+, CD11c-, CD303 (blood DC antigen [BDCA]-2)+, 
CD304 (BDCA-4)+ pDC and the CD123low, CD11high, CD1c 
(BDCA-1)+ mDC (6).
DC can secrete a diversified panel of chemokines that 
attract different cell types at different times of the immune 
response (5). They also express a unique set of costimu-
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latory molecules, which permit the activation of naive T 
cells, launching the primary immune response and polar-
izing those cells into Th1, Th2, T-regulatory cells, Th9, or 
Th17 (7). Their abilities are regulated in a process known 
as maturation, by which they modulate the tolerant or the 
effector immune responses mediated by the different sub-
types of T lymphocytes. 
Furthermore, imDC and semi-mature DC (the so-called 
partially matured DC) have been related to tolerant im-
munologic responses, while mature DC have been related 
to effector responses, but this concept seems to be more 
complex, with the probable involvement of other unknown 
factors. Semi-mature DC have been characterized as those 
that do not produce proinflammatory cytokines despite the 
expression of MHC and co-stimulatory molecules (8).
Over the past years, some authors have investigated 
DC behavior in immune responses to drugs, based on the 
hypothesis that the involved mechanism lies in very early 
events that include the interactions between imDC and the 
drug itself (4). 
Recent studies support the hypothesis that drugs interact 
differently with DC in drug-allergic and non-allergic patients 
and there is a body of evidence showing that the immu-
nologic mechanism involved in the interactions between 
imDC and the drug could modify the maturative status of 
these imDC, which could affect the lymphocyte response 
to the drug. Sanderson et al. (9) have demonstrated for 
the first time that dendritic cells are capable of activating 
intracellular sulfamethoxazole and its metabolite nitroso 
sulfamethoxazole, which is more reactive in both chemical 
and immunological terms. These investigators argued that 
this is an immunologically important pathway that is highly 
relevant to hypersensitivity, and that the potential for cross-
talk between drug metabolism and intracellular signaling in 
DC is an unexplored area that requires further investigation 
within the context of drug hypersensitivity. 
Little is known about whether drugs or drug metabo-
lites may act to generate signals that lead to activation of 
DC. Few previous studies regarding DC interaction with 
drugs have used peripheral blood mononuclear cells or 
DC generated from monocytes. Since none of them used 
purified DC subsets, the behavior of DC subsets regarding 
hypersensitivity responses to drugs remains unknown.
The exclusive expression of CD304 (BDCA-4) on pDC 
allows their direct isolation. Freshly isolated CD1c (BDCA-
1)+, CD141 (BDCA-3)+ mDC and monocytes do not express 
CD304 (BDCA-4). Like CD304 (BDCA-4), CD303 (BDCA-2) 
is specifically expressed on pDC (10).
The aim of the present report is to demonstrate the 
interaction of amoxicillin and DC subsets isolated from 
the peripheral blood of a hypersensitive patient, by means 
of IL-6 production measurement after stimulation with this 
drug and penicillin. We also demonstrate for the first time 
the feasibility of a cell purification method using blood DC 
antigen 4-positive magnetic selection and gravity filtration 
through a magnetized column for studies regarding the 
physiopathology of drug allergy. 
Material and Methods
Patient selection 
A 32-year-old female patient who experienced a se-
vere generalized maculopapular exanthema and facial 
angioedema in response to amoxicillin 10 days earlier 
was invited to participate in this study after giving informed 
written consent. The cutaneous lesions appeared on the 
3rd day of amoxicillin treatment and she denied the use 
of any other medication during this period, as well as any 
previous history of adverse drug reactions. 
The present assay was performed at the Johns Hop-
kins Asthma and Allergy Center, Johns Hopkins University, 
Baltimore, USA.
Dendritic cell purification
After venipuncture, a 150-mL blood specimen was 
processed as described previously (11,12). Briefly, this 
first involved the preparation of mixed leukocyte suspen-
sions using a double Percoll (Bio-Sciences AB, Sweden; 
1.075/1.081 g/mL) density centrifugation protocol (13). The 
basophil-depleted mononuclear cells (BDC) that floated on 
the lesser Percoll density were then recovered and washed 
free of platelets by performing 4 low-speed centrifugations 
(each 100 g, 10 min) after each wash. pDC were then puri-
fied using blood DC antigen 4-positive selection (BDCA-4; 
Miltenyi Biotec, USA). Gravity filtration through magnetized 
columns attached to a MidiMACS magnet (Miltenyi Biotec) 
facilitated the purification of this cell type. For pDC, this 
involved four washes to remove unbound (i.e., BDCA-
4 negative) cells and then removal of the column from 
the magnet and dislodging the pDC by adding buffer. An 
analysis of pDC suspensions prepared in this manner has 
previously indicated greater than 95% purity, as determined 
by BDCA-2 staining (12,14).
Cells not retained in the column during BDCA-4 selection 
(i.e., the BDCA-4 flow through) were subsequently used to 
isolate mDC with BDCA-1 selection (Miltenyi Biotec). This 
first involved depleting cell suspensions of CD19+ B cells and 
then a second pass through a different column to select for 
BDCA-1+ mDC. An analysis of mDC suspensions prepared 
in this manner had previously indicated greater than 95% 
purity, as determined by BDCA-1 staining (12).
Cells were counted using a Spiers-Levy chamber 
(Thomas Scientific, USA).
Cell culture conditions
All cultures were performed in conditioned-Iscove 
modified Dulbecco’s medium (IMDM; Life Technologies 
Inc., USA) or C-IMDM (IMDM supplemented with 5% heat-
inactivated fetal calf serum (FCS, 30 min at 56ºC; Sigma), 
1X non-essential amino acids, and 10 µg/mL gentamicin, 
966 C.M.F. Lima et al.
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pH 7.2-7.4 (Life Technologies Inc.).
BDC fractions (containing T lymphocytes and mono-
cytes), purified pDC and purified mDC suspensions were 
used for culture. The BDC fractions were cultured at ap-
proximately 5 x 106/mL in C-IMDM containing 5% FCS. 
Approximately 1.25 x 106 BDCs were added to a 96-well 
plate (0.125 mL/well; Corning Inc., USA) in a final volume 
of 0.25 mL. The purified pDC and mDC were cultured at 
approximately 1 to 105/mL in C-IMDM containing 5% FCS. 
Approximately 25 to 50 x 103 purified pDC or mDC were 
added to a 96-well plate (0.125 mL/well) in a final volume of 
0.25 mL. After incubating for 15 min to equilibrate to 37ºC 
in the presence of 5% CO2, an equal volume of stimulus or 
C-IMDM was added into duplicated cultures. Amoxicillin was 
used as the stimulus at pre-determined concentrations, i.e., 
500, 100 and 10 µg/mL. To achieve these concentrations, 
a 500-mg amoxicillin capsule (GlaxoSmithKline, UK) was 
diluted in 50 mL saline and underwent a pH correction to 
approximately neutral, resulting in a uniform suspension 
of 12.5 mg/mL aliquots. This was subsequently diluted 
with C-IMDM.
Vancomycin hydrochloride (Novaplus, USA) was used 
as negative control at 5, 50, 250, and 500 µg/mL. Lyophilized 
vancomycin hydrochloride was diluted in 10 mL saline and 
used in 50 mg/mL aliquots, progressively diluted with C-
IMDM to achieve the concentrations cited above.
The monoclonal anti-FcεRI antibody (eBioscience, 
USA) at 1:167 (75 ng/mL) was used as a positive control 
in all culture wells. CpG ODN-2216 type A class (100 nM; 
Tri-Link, USA) was added as a positive control to culture 
wells containing BDC and pDC suspensions. Peptidoglycan 
(Invitrogen Life Technologies, USA) at 10 µg/mL was used 
as a positive control only in culture wells containing mDC 
suspensions. Previous studies from our laboratory have 
demonstrated that peptidoglycan is more efficient in stimulat-
ing mDC suspension cells than is CpG, a finding likely due 
to the absence of Toll-like receptor 9 (TLR9) in mDC. 
Because amoxicillin is a synthetic penicillin, crystal-
line penicillin G (Roerig Division of Pfizer Inc., USA) was 
used as an additional stimulus reconstituted in 8.2 mL of a 
standard diluent, in aliquots of 500,000 IU/mL and diluted 
with C-IMDM at concentrations of 20, 200, and 1000 IU/
mL. After a 20-h incubation period, the supernatants were 
harvested and frozen at -70ºC to be ultimately assayed 
for cytokines. For this preliminary study we assayed IL-6 
levels using ELISA (eBioscience ELISA commercial kit; 
eBioscience).
Results
BDC suspensions
IL-6 production was observed in BDC suspensions after 
stimulation with the anti-FcεRI and CpG-positive controls. 
Anti-FcεRI was a more potent stimulus of IL-6 production 
than CpG. On the other hand, IL-6 production was not 
observed after stimulation with amoxicillin and penicillin, 
or after stimulation with vancomycin used as a negative 
antibiotic control. 
pDC suspensions
The dose-response curve for IL-6 production after 
stimulation with penicillin had a higher magnitude than the 
curve observed after amoxicillin stimulation. The positive 
anti-FcεRI control demonstrated more potent stimulation 
for this cell suspension than CpG (Figure 1). 
mDC suspensions
The purified mDC suspension only secreted IL-6 after 
stimulation with positive anti-FcεRI controls and peptido-
glycan. The latter was more potent than the former. No IL-6 
secretion was observed after stimulation with vancomycin 
as the negative control or after stimulation with amoxicillin 
and penicillin (Figure 2).
Discussion
We propose the use of a standardized DC subset isola-
tion method, comprised of magnetic selection and gravity 
filtration, in studies regarding drug hypersensitivity reaction 
mechanisms.
This method provides a pDC suspension with 95% ho-
mogeneity (12), which is high compared to other methods. 
This DC subset is very difficult to use because of its low 
frequency in peripheral blood. Also the potential for con-
tamination with endotoxin from some biological substances 
used as a stimulus, like mite or milk proteins, has been a 
challenge for in vitro studies regarding DC immunobiol-
ogy, since these substances may activate TLR leading to 
false-positive results. This contamination, however, does 
not seem to occur with drugs. 
In this assay, we observed a positive dose-response 
curve for IL-6 production by pDCs harvested from a hy-
persensitive subject after stimulation with penicillin and 
amoxicillin. However, it was not observed on mDC and BDC 
suspensions, despite the positive response after stimulation 
with positive controls. 
In order to exclude toxic effects or non-specific stimuli 
induced by drugs in the DC subsets, vancomycin was used 
as negative control, since the subject did not have any his-
tory of vancomycin use. 
The amoxicillin concentration used to stimulate DC in 
this assay was based on the studies of Rodriguez-Pena et 
al. (4), using DC cultivated from monocytes. These investi-
gators suggested an active influence of amoxicillin on the 
maturational status of DC and demonstrated phenotypic 
and functional changes in DC cultivated from monocytes 
from hypersensitive patients, after in vitro stimulation with 
amoxicillin. In their study, amoxicillin seemed to direct DC 
from sensitive patients to a semimature phenotypic status, 
with increased expression of maturation and activation 
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Figure 1. Concentration of IL-6 (pg/106 cells) produced by the suspension of plasmacytoid dendritic cells (pDC). Concentration (Conc.) 
1: 20 IU/mL penicillin, 5 µg/mL vancomycin, 5 µg/mL amoxicillin, 75 ng/mL anti-FcεRI/mL, and 100 nM CpG. Concentration 2: 200 IU/
mL penicillin, 50 µg/mL vancomycin, and 50 µg/mL amoxicillin. Concentration 3: 1000 IU/mL penicillin, 250 µg/mL vancomycin, and 
250 µg/mL amoxicillin.
Figure 2. Concentration of IL-6 (pg/106 cells) produced by the suspension of myeloid dendritic cells (mDC). Concentration (Conc.) 1: 
20 IU/mL penicillin, 5 µg/mL vancomycin, 5 µg/mL amoxicillin, 75 ng/mL anti-FcεRI/mL, and 10 µg/mL peptidoglycan. Concentration 2: 
200 IU/mL penicillin, 50 µg/mL vancomycin, and 50 µg/mL amoxicillin. Concentration 3: 1000 IU/mL penicillin, 250 µg/mL vancomycin, 
and 250 µg/mL amoxicillin.
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markers (HLA-DR, CD86, and CD80) and an increased 
endocytosis ability. However, amoxicillin was not capable 
of inducing complete maturation of these culture-derived 
DC when compared with other agents that interact directly 
with specific receptors such as lipopolysaccharide and TNF. 
This finding is consistent with the semi-mature status de-
scribed by Lutz and Schuler (8) and leads us to speculate 
that amoxicillin might play a fundamental role in triggering 
the maturational process, or in the generation of signals in 
patient imDC that could induce the release of inflammatory 
mediators that activate DC (4). These investigators also 
suggest that, in an appropriate environment, amoxicillin acts 
not only as an antigen but also as a maturation stimulus.
In the present study, amoxicillin was not as potent a 
stimulus as the positive control or penicillin. Surprisingly, 
the latter stimulus was more potent than amoxicillin for 
pDC suspensions, and the IL-6 values were higher than 
the positive control CpG-ODN, even though the subject 
had denied any history of previous reaction to penicillin. 
However, further studies will be necessary to optimize 
the penicillin and amoxicillin concentration to be used for 
stimulation. To our knowledge, these antibiotics have never 
been used for in vitro DC stimulation. 
These results encouraged us to develop a similar study 
with a greater number of subjects in order to study pDCs 
behavior on drug hypersensitive reactions. The interaction 
of DC with drugs is an emerging area of research, which 
can bring new insights, not only for the understanding of 
adverse drug reaction physiopathology, but also to improve 
the current knowledge of DC immunobiology.
Additionally, Aubert et al. (15) demonstrated that DC 
pulsed with neuromuscular blocker agents were able 
to induce a significant proliferative T-cell response in 
two hypersensitive subjects. This suggests that a better 
understanding of the DC activation mechanisms in drug 
hypersensitivity reactions may lead to improved efficacy 
of the lymphocyte transformation test in the identification 
of the culprit drug.
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